These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16178992)

  • 1. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darifenacin in the treatment of overactive bladder.
    Parsons M; Robinson D; Cardozo L
    Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of solifenacin in the treatment of overactive bladder.
    Robinson D; Cardozo L
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1339-48. PubMed ID: 15461562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F; Cardozo L; Chapple C; Ridder AM;
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
    Millard RJ; Halaska M
    Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
    Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T
    Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
    Brunton S; Kuritzky L
    Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
    Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM
    BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin at 3 years: a review of efficacy and safety.
    Pelman RS; Capo JP; Forero-Schwanhaeuser S
    Postgrad Med; 2008 Jul; 120(2):85-91. PubMed ID: 18654073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR; Te AE
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solifenacin and darifenacin for overactive bladder.
    Med Lett Drugs Ther; 2005 Mar; 47(1204):23-4. PubMed ID: 15767976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.